Nose-to-brain formulations

FormulationActive PharmaceuticalPharmacological EffectsReferences
SolutionsInsulinImproved memory in AD patientsCraft et al., 2012
InsulinIncreased cognition in pediatric patients with 22q13 deletion syndromeSchmidt et al., 2009
InsulinReduced nicotine craving in smokersHamidovic et al., 2017
OxytocinReduced the PTSD response in humansSack et al., 2017; van Zuiden et al., 2017
OxytocinImproved ability to emotionally rate faces in patients with ASDQuintana et al., 2017
Solid lipid nanoparticlesValproic acidProtects against seizures in a rat seizure modelEskandari et al., 2011
Chitosan nanoparticlesPramipexoleCorrected motor deficits in a rat model of Parkinson’s disease; an enhanced pharmacological response when compared with the drug in solutionRaj et al., 2018
Plasmid encoding for red fluorescent proteinGene expression in the striatal region of mice brainsSanchez-Ramos et al., 2018
MET nanoparticlesLENKAntinociception in spinal, thermal, and paw inflammation pain mouse and rat modelsGodfrey et al., 2018
PropofolSedation in a healthy rat modelUchegbu et al., 2014
PLGA nanoparticlesOxcarbazepineReduced seizures in a rat seizure modelMusumeci et al., 2018
PLGA nanoparticles coated with trimethyl chitosanHuperzine AIncreased brain exposure when compared with uncoated PLGA nanoparticlesMeng et al., 2018